Filing Flows › AtriCure (ATRC) › Q2 2026 › vs Q2 2025
AtriCure (ATRC) Q2 2026 vs Q2 2025 (year over year)
AtriCure's revenue rose $17.5M (+13%) from $136M in Q2 2025 to $154M in Q2 2026. Gross margin 77.2% against 74.5% (+2.7 pts).
AtriCure, Q2 2026: revenue $154M (+13% year over year), operating margin 6.3%, net earnings $9.0M, operating cash flow $22.2M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 77.2% | 74.5% | +2.7 pts |
| Operating margin | 6.3% | -4.5% | +10.8 pts |
| Net margin | 5.8% | -4.5% | +10.4 pts |
| Free cash flow margin | 12.0% | 13.9% | -1.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $154M | $136M | $17.5M | +13% |
| Gross profit | $119M | $101M | $17.1M | +17% |
| Cost of revenue | $35.0M | $34.7M | $318K | +0.9% |
| Operating profit | $9.7M | −$6.2M | $15.9M | — |
| Operating expenses | $109M | $108M | $1.3M | +1% |
| Pre-tax earnings | $9.4M | −$5.9M | $15.4M | — |
| Research & development | $26.4M | $29.3M | −$2.9M | -10% |
| SG&A | $82.6M | $78.4M | $4.2M | +5% |
| Net earnings | $9.0M | −$6.2M | $15.1M | — |
| Income tax | $471K | $261K | $210K | +80% |
| Depreciation & amortization | $5.3M | $5.2M | $136K | +3% |
| Share-based compensation | $12.3M | $11.4M | $942K | +8% |
| Working capital & other | $4.4M | −$11.3M | $15.6M | — |
| Operating cash flow | $22.2M | $21.6M | $575K | +3% |
| Free cash flow (OCF − capex) | $18.4M | $19.0M | −$529K | -3% |
| Capital expenditures | $3.8M | $2.7M | $1.1M | +41% |
Questions
How much did AtriCure's revenue grow year over year in Q2 2026?
AtriCure's revenue rose $17.5M (+13%) from $136M in Q2 2025 to $154M in Q2 2026. Gross margin 77.2% against 74.5% (+2.7 pts).